Daniel Kaschek;Frauke Henjes;Max Hasmann;Ulrike Korf;Jens Timmer
{"title":"Testing the Pattern of AKT Activation by Variational Parameter Estimation","authors":"Daniel Kaschek;Frauke Henjes;Max Hasmann;Ulrike Korf;Jens Timmer","doi":"10.1109/LLS.2016.2615081","DOIUrl":null,"url":null,"abstract":"Dynamic modeling has become one of the pillars of understanding complex biological systems from a mechanistic point of view. In particular, ordinary differential equations are frequently used to model the dynamics of the interacting states, e.g., molecular species in cell signaling pathways. The equations typically contain many unknown parameters, such as reaction rates and initial conditions, but also time-dependent parameters, i.e., input functions driving the system. Both are \n<italic>a priori</i>\n unknown and need to be estimated from experimental, time-resolved data. Here, we discuss an application of indirect optimal control methods for input estimation and parameter estimation in the \n<italic>mammalian target of rapamycin</i>\n (mTOR) signaling. Whereas the direct identification and quantification of different active mTOR complexes, e.g., \n<italic>mTOR complex</i>\n \n<inline-formula> <tex-math>$\\textit {2}$ </tex-math></inline-formula>\n (mTORC2), is only possible by highly challenging experiments, the mathematical framework allows to reconstruct its dynamics by solving an appropriate Euler–Lagrange equation based on Pontryagin’s maximum principle. The inherently large search space underlying this approach allows to test specific biological hypotheses about the activation of \n<italic>protein kinase B</i>\n (AKT) by mTORC2 and to reject an alternative model with high statistical power. Hereby, we identify a minimal model that has AKT threonine phosphorylation as a prerequisite for serine phosphorylation by mTORC2. Based on this model, the activation of mTORC2 is predicted to be inhibited by drugs, targeting the receptors of the ERBB receptor family.","PeriodicalId":87271,"journal":{"name":"IEEE life sciences letters","volume":"2 2","pages":"13-16"},"PeriodicalIF":0.0000,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1109/LLS.2016.2615081","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IEEE life sciences letters","FirstCategoryId":"1085","ListUrlMain":"https://ieeexplore.ieee.org/document/7740930/","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Dynamic modeling has become one of the pillars of understanding complex biological systems from a mechanistic point of view. In particular, ordinary differential equations are frequently used to model the dynamics of the interacting states, e.g., molecular species in cell signaling pathways. The equations typically contain many unknown parameters, such as reaction rates and initial conditions, but also time-dependent parameters, i.e., input functions driving the system. Both are
a priori
unknown and need to be estimated from experimental, time-resolved data. Here, we discuss an application of indirect optimal control methods for input estimation and parameter estimation in the
mammalian target of rapamycin
(mTOR) signaling. Whereas the direct identification and quantification of different active mTOR complexes, e.g.,
mTOR complex
$\textit {2}$
(mTORC2), is only possible by highly challenging experiments, the mathematical framework allows to reconstruct its dynamics by solving an appropriate Euler–Lagrange equation based on Pontryagin’s maximum principle. The inherently large search space underlying this approach allows to test specific biological hypotheses about the activation of
protein kinase B
(AKT) by mTORC2 and to reject an alternative model with high statistical power. Hereby, we identify a minimal model that has AKT threonine phosphorylation as a prerequisite for serine phosphorylation by mTORC2. Based on this model, the activation of mTORC2 is predicted to be inhibited by drugs, targeting the receptors of the ERBB receptor family.